Virologist Marie-Louise Hammarskjold of the UVA School of Medicine, who sat on a National Institutes of Health panel that approved the strategy, agrees that the safety data are convincing. “They had pretty good evidence, based on animal and cell culture experiments, that the off-target effects wouldn't be such a high risk that [the trial] was not worth trying,” she said.